Technical Analysis for MDXH - MDxHealth SA
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 2.88 | 0.70% | 0.02 |
Earnings due: Jun 5
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| NR7 | Range Contraction | 0.70% | |
| Wide Bands | Range Expansion | 0.70% | |
| 20 DMA Support | Bullish | 2.31% | |
| Inside Day | Range Contraction | 2.31% | |
| Wide Bands | Range Expansion | 2.31% | |
| 20 DMA Support | Bullish | 0.00% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | 1 day ago |
| Possible NR7 | 1 day ago |
| Rose Above Previous Day's High | 1 day ago |
| Up 2% | 1 day ago |
| Up 1% | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 06/05/2024
MDxHealth SA Description
MDxHealth SA operates as a molecular diagnostics company in Belgium, the Netherlands, Spain, Poland, Italy, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on proprietary genetic, epigenetic, and other molecular technologies, as well as assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company's product pipeline includes tests for bladder, kidney, and other urologic cancers. Its products include ConfirmMDx, a tissue test for prostate cancer; and SelectMDx, a non-invasive urine test for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancer Clinical Medicine Prostate Cancer Medical Genetics Urology Molecular Diagnostics Molecular Technologies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.256 |
| 52 Week Low | 2.21 |
| Average Volume | 72,353 |
| 200-Day Moving Average | 17.36 |
| 50-Day Moving Average | 2.65 |
| 20-Day Moving Average | 2.76 |
| 10-Day Moving Average | 2.92 |
| Average True Range | 0.18 |
| RSI (14) | 53.92 |
| ADX | 19.18 |
| +DI | 21.88 |
| -DI | 21.22 |
| Chandelier Exit (Long, 3 ATRs) | 2.65 |
| Chandelier Exit (Short, 3 ATRs) | 2.76 |
| Upper Bollinger Bands | 3.26 |
| Lower Bollinger Band | 2.27 |
| Percent B (%b) | 0.62 |
| BandWidth | 35.98 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.04 |
| MACD Histogram | 0.0159 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.99 | ||||
| Resistance 3 (R3) | 2.99 | 2.96 | 2.97 | ||
| Resistance 2 (R2) | 2.96 | 2.93 | 2.96 | 2.96 | |
| Resistance 1 (R1) | 2.92 | 2.92 | 2.94 | 2.92 | 2.96 |
| Pivot Point | 2.89 | 2.89 | 2.90 | 2.89 | 2.89 |
| Support 1 (S1) | 2.85 | 2.86 | 2.87 | 2.85 | 2.80 |
| Support 2 (S2) | 2.82 | 2.85 | 2.82 | 2.80 | |
| Support 3 (S3) | 2.78 | 2.82 | 2.79 | ||
| Support 4 (S4) | 2.78 |
